46 results about "Primary hepatic carcinoma" patented technology

The invention belongs to the genetic engineering and tumour medicine fields and discloses an SNP marker related to primary hepatocellular carcinoma auxiliary diagnosis and an application of the SNP marker. The marker is a combination of rs7574865, rs1012068, rs17401966, rs2596542, rs455804, rs9272105, rs9275319 and rs9275572. The marker can be used for preparing a hepatic carcinoma auxiliary diagnosis kit.

The invention provides a human tumor stem cell line T3A-A3, which is obtained by separation of liver cancer tissue excised in an operation of a primary hepatic carcinoma patient. The separated cells can be in long-term passage culture in vitro, can grow rapidly and retain stem cell property after more than 100 times of passage. The cell can express markers of multiple stem cells, has self-updatingcapability of stem cells and directional differentiation potentials for different tumor cells, and also has tumor property, tumorigenicity ability and metastatic ability. The invention is a powerfultool for preparing stem cell drugs for targeting tumor, due to the facts that the cells can be in long-term passage culture in vitro and retain unchanged stem cell property, and the tumorigenicity ability and metastatic ability thereof are strong in immunodeficient mice.

The invention relates to the technical field of biomedical diagnostics and discloses a reagent kit for detecting a serum marker of primary hepatic carcinoma, which consists of an ELISA plate enveloped by antigens, an enzyme-labeled antibody working solution, a sample diluent, a washing liquid, positive and negative control serum, a chromogenic solution and a stopping liquid. The reagent kit is characterized in that the envelope antigens of the ELISA plate are five groups of peptide antigens L4-A and L4-B; L7-B; L11-1, L11-3 and L11-4; L12-A and L12-B; and Sui1-A and Sui1-B, which correspond to five serum marker antibodies of the primary hepatic carcinoma; and Sui1-A and Sui1-B respectively. Except the L7B which is separately enveloped, each group of all the other groups of peptide antigens is enveloped by proportionally mixing polypeptides in the same group. Proven by evaluation experiments of the reagent kit and clinical trial, the reagent kit has good specificity and sensitivity, and can be used for early warning prompt or early diagnosis before the primary hepatic carcinoma appears or at early stage of the primary hepatic carcinoma, thereby improving the survival rate of carcinoma patients and evaluating treatment effect and disease outcome in time by observing the dynamic change of related indicators of the serum.

The invention discloses a medicine for treating primary hepatic carcinoma. The medicine is prepared from the following medicinal raw materials: codonopsis pilosula, astragalus membranaceus, human placenta, radix paeoniae alba, fructus lycii, radix bupleuri, fingered citron, silybum marianum, lysimachia christinae hance, corn stigma, pericarpium citri reticulatae, rhizoma atractylodis macrocephalae, fructus aurantii, angelica sinensis, corydalis tuber, safflower carthamus, salviae miltiorrhizae, turtle shell, oldenlandia diffusa, sculellaria barbata, selfheal, dandelion, edible tulip, pericarpium citri reticulatae viride, kelp, myrrh and licorice root. The medicine is prepared from a prescription of pure traditional Chinese medicinal materials, has small toxic and side effect, and can be used for improving the living quality of patients with primary hepatic carcinoma in middle and advanced stage to prolong the lives of patients and curing early primary hepatic carcinoma. The total effective rate of the medicine for treating primary hepatic carcinoma is 100 percent.

The invention belongs to the technical field of immunoassay analysis and particularly relates to an immunosensor based on photonic crystal fibers as well as a manufacturing method and application thereof. The manufacturing method comprises the following steps: combining an alpha-fetoprotein antibody Abl on the PCF inner surface through a covalent bond, adding an antigen and a fluorescent labeled second antibody (Ab2) sequentially, forming a sandwich structure Ab1-AFP-Ab2 through the interaction between the antibody and the antigen, and quantitatively detecting a tumor marker AFP of primary hepatic carcinoma (PHC). Compared with an existing product and the prior art, the photonic crystal optical fiber immunosensor has the benefits that the whole preparation process is simple and suitable for industrial production; the antigen concentration is positively correlated with the fluorescence intensity, so that the alpha-fetoprotein can be qualitatively and quantitatively detected; the operation in the detection process is very simple and convenient, and the needs of higher detection sensitivity can be met, therefore, an important clinical diagnostic significance is realized.

The invention discloses a human hepatocellular carcinoma cell line, and an establishing method and application thereof. The human hepatocellular carcinoma cell line is preserved in China Center for Type Culture Collection with an accession number of CCTCC No: C201114. The establishing method comprises the following steps: 1) acquiring a fresh clinical liver cancer excision specimen, cutting the specimen into small blocks with sizes in a range of 20 to 50 mg and inoculating mammals with the small blocks; and 2) in 70 to 90 d after inoculation, killing tumor-bearing mammals, taking out tumor tissue and carrying out primary culture and subculturing of cancer cells. The human hepatocellular carcinoma cell line provided by the invention has stable properties and tumorigenicity, can realize stable several passages and successful preparation of a liver cancer animal model, can be used for analyzing in-vivo and in-vitro drug susceptibility so as to further realize establishment of mutually-related in-vivo and in-vitro drug screening platforms, and is an ideal human primary hepatic carcinoma cell line applied to fundamental research and preclinical application.

The present invention relates to the field of microbial animal cells, and specifically a hepatoma cell line STL-C1 derived from human hepatoma para-carcinoma tissue. The cell line has a preservation number CCTCC No:C201630. The present invention also provides an establishment method and application of the cell line. The established hepatoma cell line STL-C1 is derived from human hepatocellular hepatoma para-carcinoma tissue, and can be cultured in vitro for a long term and has stable passage; and in vivo experiments show that the cell line still has good tumorigenic property, and is completely different from the currently existing established common hepatoma cell lines and even from the hepatoma cancer embolus cell line. The hepatoma cell line STL-C1 has important usage and reference value to the study of the formation of satellite lesions, and biological behaviors suahc as recurrence and transfer of primary hepatic carcinoma, is a novel cell model for basic and clinical research of hepatoma, and has broad application prospects.

The invention provides an establishment method of a primary liver cancer mouse model and relates to an establishment method of a liver cancer mouse model. The invention solves the problems of an existing establishment method of the primary liver cancer mouse model that the establishment time is long, the feeding cost is high, and the death easily occurs in feeding. The establishment method comprises the following steps of: 1, selecting a 4-week-old ICR (Institute for Cancer Research) male mouse, and observing and feeding the mouse for 2 weeks; 2, after the male mouse is fed for 2 weeks, determining the body weight of each mouse and the daily water intake; 3, disinfecting the abdomen of the mouse by using alcohol cotton with a volume concentration of 75 percent, injecting DEN (Diethylnitrosamine) aqueous solution into an abdominal cavity, enabling the mouse to drink water containing DEN with a volume concentration of 0.15 percent after 12 hours and feeding for 4 weeks; 4, after 4 weeks, injecting the DEN aqueous solution into the abdominal cavity again, then feeding and drinking the water containing the DEN freely during the feeding period; 5, feeding to 10 weeks as of the day of injecting the DEN aqueous solution for the first time to obtain the primary liver cancer mouse model. The establishment method is also used for establishing an in-situ liver cancer animal model.

The invention belongs to the technical field of medical products, and particularly relates to application of DDX24 and upstream and downstream molecules RFX8 and Lamb1 thereof in diagnosis and treatment of hepatocellular carcinoma. Researches find that compared with paracancerous normal tissues, primary hepatic carcinoma tissues are increased in DDX24 expression level, and the increased level is related to tumor size; and survival analysis shows that RFX8 can up-regulate DDX24 expression at the transcription level, and miR-526a-5p can be directly combined with mRNA of DDX24 and degrade the mRNA of DDX24. According to the application, DDX24 can promote the development of HCC through a downstream LAMB1 pathway, and the research of the pathway is expected to provide a theoretical basis and anexperimental basis for the diagnosis and treatment of HCC.

The invention relates to a multifunctional balloon catheter integrated with a puncture needle and a system. The balloon catheter adopting unique design and the system can be used for different types of tumor such as benign and malignant bile duct stenosis, esophagus cancer, colorectal cancer, bronchogenic carcinoma, gastric antrum cancer, portal vein and vena cava tumor thrombus of primary hepatic carcinoma and the like, a far-end part where an eccentric balloon and the puncture needle are located is precisely put in the part where tumor of a lumen is located, a swelling balloon pushes the far end of the puncture needle to attach to the tumor, a near end of a rotating system operates a nut of the system and pushes the puncture needle to extend out of the catheter, the far end of the puncture needle with shape memory is bent and punctures the tumor, the puncture needle can be used for injecting a tumor treatment drug into the tumor to treat tumor or sucking tissue for biopsy or is used as a radiofrequency ablation electrode to perform radiofrequency ablation / heating to treat the tumor; on the basis of the system, with the adoption of different designs, the multifunctional balloon catheter can be used for injection of the treatment drug into atherosclerosis plaques and treatment of aortic dissecting aneurysm.

The invention relates to a prognosis condition grouping method for primary liver cancer radical resection, a device and a system. The method is used for evaluating a prognosis recurrence risk of a primary liver cancer patient who is going to bear a tumor radical resection or has bear the tumor radical resection based on combined testing of cytokeratin (CK19) and glypican-3 (GPC3), number of tumorsand blood vessel invasion as indexes. According to the method, reasonable screening can be performed on the patient before surgery, thereby reducing metastasis and recurrence after tumor radical resection. Furthermore the method can be used for evaluating the tumor metastasis and recurrence risk of the primary liver cancer patient, and furthermore guides a clinical doctor in performing close monitoring and early-period processing on the cases with high metastasis and recurrence risk.

The invention relates to a gene marker of predicting primary hepatic carcinoma metastatic potential. By detecting the gene expression profile level of no metastatic carcinoma tissue samples and metastatic carcinoma tissue samples from a primary hepatic carcinoma patient, the inventor screens out 14 specific genes for the first time by virtue of a statistical analysis method, the test result proves that the gene marker can be very effectively used in predicting the hepatic carcinoma metastatic situation or metastatic potential of the primary hepatic carcinoma patient.

The invention relates to an improvement for a preparation method of a Chinese material medical preparation for treating primary hepatic carcinoma, the Chinese material medical preparation comprises the following raw materials: Codonopsis pilosula, white atractylodes rhizome, ground beeltle, Sculellaria barbata, semen coicis, oyster, rhizoma cyperi, turtle shell, Astragalus mongholicus, rheum officinale, herba patriniae, radix curcumae, oriental wormwood, capillary Artemisia, agilawood, Paris polyphylla, pericarpium citri reticulatae, Poria cocos, Sappan Wood, caulis clematidis armandii, peach kernel and radix bupleuri; agilawood fine powder employs a superfine crushing method on the basis of a traditional preparation method, a drying process employs microwave vacuum drying. The problems of incompletely extraction of effective constituents, low solubility of the agilawood fine powder, storage of traditional Chinese medicine volatile oil, drying of volatile organic constituents, so that the bioavailability of the preparation is increased.

An oleum fructus bruceae fat emulsion concentrated solution, a preparation method and an application thereof belong to the field of pharmacology and pharmaceutics. According to the invention, the defect that a traditional fat emulsion preparation technology is complex and stability is poor is overcome. The preparation technology provided by the invention is simple; the general physical stirring process is only needed; and no homogenization technology is required. A product prepared in the invention can be sterilized through a 0.22-micron microfiltration membrane; in clinical use, the product can be spontaneously emulsified after diluted by the use of an aqueous solution such as normal saline or a glucose solution, etc. and slightly oscillated; and under optimized conditions, average particle size is about 0.2 micron, and injection fat emulsion characteristics are fully embodied. The product has good fluidity, will not be retained on the wall, is single-phase, transparent and clear in appearance, can undergo clarification detection, will not cause preparation stratification after multigelation and is used for treating diseases such as stomach cancer, esophagus cancer, primary hepatic carcinoma, colorectal cancer, pancreas cancer, lung cancer, cervical carcinoma, bladder cancer, prostate cancer and other solid tumor metastatic cancer, etc.

The invention relates to a traditional Chinese medicine agent for treating primary hepatic carcinoma. The invention adopts the technical scheme that the traditional Chinese medicine agent is prepared from the following traditional Chinese medicines in part by weight: prayer beads, herba saururi chinensis, verbena, grangea all-grass, stringy stonecrop herb, lawn pennywort herb, catclaw buttercup roots, radix sophorae tonkinensis, Chinese pulsatilla roots, nightshade, oldenlandia diffusa, patrinia heterophylla, fevervine, hyacinth beans, radix astragali, bighead atractylodes rhizome, wild buckwheat, mangnolia officinalis, parched hawthorn fruits, Chinese honeylocust spine, dried green tea, calabash, elephantopus scaber, nidus vespae, sea tangle, star-of-Bethlehem, Chinese dates, dried orange peel and red beans. Besides, the traditional Chinese medicine agent has the functions of relieving swellings, clearing away toxic substances, dredging stagnation, removing stasis, stopping pain, reducing phlegm, soothing liver, promoting qi circulation and dredging congestion, and is used for treating various liver and gall diseases, such as jaundice, hepatitis, gallstone, cholecystitis, cirrhosis and hepatic carcinoma. The traditional Chinese medicine agent has remarkable therapeutic effect, is lower in cost, and solves health and safety problems for many patients with the liver and gall diseases.

The invention discloses a preparation method of an AFP / HBsAg double-targeting Dexosome anti-hepatoma anti-tumor vaccine. A novel double-targeting anti-hepatoma anti-tumor vaccine is prepared by the following steps: by using a recombinant human adenovirus vector as one target of a hepatoma associated antigen AFP gene and combining the characteristics of primary hepatic carcinoma of China, combining a specific antigen HBsAg of hepatoma associated virus as an immune immunotherapy target; importing DC; and extracting Dexosome, wherein the anti-hepatoma immunological effect induced is enhanced. The novel Dexosome anti-tumor vaccine can be combined with an antigen peptide at the same time through MHC-I / II molecules, so that not only can the CD8+cytotoxic T cell be activated, but also the CD4+auxiliary T cell can be activated. The method overcomes the problems in the prior at that the immunological effect induced by a single tumor antigen is weak, DC is complex to prepare and the like and is a preparation method of a novel non-cellular Dexosome anti-hepatoma anti-tumor vaccine.

The invention provides a GP73 antigen silicon-based magnetic bead conjugate as well as a competition method GP73 quantitative determination kit formed by taking the conjugate as one of the components and matching with other components. The kit disclosed by the invention consists of a Golgi protein 73 (GP73) antigen silicon-based magnetic bead conjugate working solution, a Golgi protein 73 (GP73) calibration material, an alkaline phosphatase labeled Golgi protein 73 (GP73) monoclonal antibody working solution, a cleaning solution and a chemiluminescence substrate. Meanwhile, the invention provides a method for preparing the GP73 antigen silicon-based magnetic bead conjugate and a method for preparing each component in the kit. The method comprises the following steps: preparing the GP73 antigen silicon-based magnetic bead conjugate working solution, preparing an enzyme-labeled antibody, preparing the calibration material, preparing the cleaning solution and preparing the chemiluminescence substrate. The kit provided by the invention can be mainly applied to diagnosis of primary hepatic carcinoma and has the advantages of high sensitivity, wide linear range, hook effect avoidance, low cost, short detection time consumption and the like.

The invention discloses a Chinese traditional medical composition for treating primary hepatic carcinoma. The Chinese traditional medical composition comprises the effective components of sculellaria barbata, Indian strawberry, nightshade, roasted nightshade, prepared pinellia ternate, ternate buttercup root, radix curcumae, polygonum cuspidatum, mistletoe, rhizoma atractylodis macrocephalae, fingered citron, wartwort and fructus ligustri lucidi. The Chinese traditional medical composition provided by the invention can be particles, capsules, troches, pills or oral solutions and has the effects of inhibiting proliferation of hepatoma carcinoma cells and promoting aging, apoptosis and anoikis of the hepatoma carcinoma cells and can be used to treat the primary hepatic carcinoma. The invention further discloses a preparation method of the Chinese traditional medical composition.

The invention relates to an internal cooling microwave catheter capable of monitoring temperature in real time and a system. Aiming at tumors in the hollow organs including the bile duct, the esophagus, the colorectum, the sinuses ventriculi and the like, the invention provides a microwave catheter fixedly provided with an eccentric sacculus at the far end of a catheter body and a system, the eccentric sacculus and a microwave emission part are accurately placed at the position where the tumor of the lumen is located for treatment, aiming at primary hepatic carcinoma portal vein and vena cavacancer embolus, partial modification is made on the basis of the balloon catheter and the system, a hydrophilic super-lubricant guide wire capable of forming a loop at the far end of the catheter replaces the eccentric sacculus, and a microwave antenna and a thermocouple temperature probe are pushed for attaching to the cancer embolus in the vessel lumen or the tumor in the tracheal bronchus lumenfor treatment.

The invention provides a stasis and stagnation eliminating decoction for treating primary hepatic carcinoma. The decoction is mainly prepared from the following raw medicinal materials in parts by weight: 22 parts of herba artemisiae scopariae, 26 parts of polygonum cuspidatum, 18 parts of dandelion and 16 parts of herba patriniae, or 22 parts of herba artemisiae scopariae, 26 parts of polygonum cuspidatum, 18 parts of dandelion, 16 parts of herba patriniae, 30 parts of hedyotis diffusa and 25 parts of lonicera japonica, as well as 17 parts of salviae miltiorrhizae, 22.5 parts of roasted turtle shell and 12.5 parts of szechwan Chinaberry fruit, or 17 parts of salviae miltiorrhizae, 22.5 parts of roasted turtle shell, 12.5 parts of szechwan Chinaberry fruit, 14 parts of rhizoma sparganii, 20 parts of curcuma zedoary, 17.5 parts of radix bupleuri, 13.5 parts of radix curcumae, 11 parts of pericarpium citri reticulatae viride, 18.5 parts of dried tangerine peel and 20 parts of radix paeoniae alba. The medicinal materials are mixed, added with liquorice, decocted and concentrated to prepare the decoction. The whole medicinal formula of the decoction can be used for eliminating evil factors without hurting body resistance and strengthening body resistance without leaving evil factors, plays roles in clearing heat, promoting diuresis, removing toxicity, soothing liver, regulating qi, strengthening spleen, activating blood circulation to remove stasis and resolving hard lump, and is used for eliminating stasis and stagnation and treating primary hepatic carcinoma.

The invention discloses application of a fructus akebiae extract in preparation of a drug for treating primary hepatic carcinoma. The application is that the fructus akebiae extract is taken as an active ingredient to prepare a drug preparation for treating the primary hepatic carcinoma. A cancer cell growth and proliferation MTT (methyl thiazolyl tetrazolium) detection method is adopted by the invention, and the experiment demonstrates that the fructus akebiae extract has the significant effect of restraining malignant cell proliferation of the primary hepatic carcinoma, and is expected to be applied to preparation of the drug preparation for treating the primary hepatic carcinoma by restraining the malignant cell proliferation of the primary hepatic carcinoma; and a new medicinal value is opened up for the fructus akebiae extract.

The invention discloses a traditional Chinese medicine for treating TACE (Transcatheter Arterial Chemoembolization) postoperation toxic and side effects of primary hepatic carcinoma. The traditional Chinese medicine consists of codonopsis pilosula, atractylodes macrocephala, poria cocos, astragalus membranaceus, radix bupleuri, radix paeoniae alba, radix salviae miltiorrhizae, chicken's gizzard-membranes, glossy privet fruits, radix saposhnikoviae, lucid ganoderma and borneol. The components play roles of strengthening spleen and tonifying liver, clearing liver and regulating qi, clearing heatand removing toxin as well as removing stasis and eliminating stagnation, and TACE postoperation toxic and side effects of primary hepatic carcinoma can be remarkably alleviated.

The invention relates to new medical application of bear gall powder, namely an application of bear gall powder in preparation of a medicament capable of preventing and treating transhepatic arterial chem otherapy and embolization (TACE) failed back surgery syndrome of primary hepatic carcinoma patients. The invention has the advantages that clinical research indicates that bear gall powder is capable of obviously improving the TACE failed back surgery syndrome of primary hepatic carcinoma patients, reducing the glutamicoxalo acetictransaminase level, protecting the liver function and reducing the inflammatory factor level for the first time, and has the application prospect of preventing and treating transhepatic arterial chem otherapy and embolization (TACE) failed back surgery syndrome of primary hepatic carcinoma patients.

The invention belongs to the genetic engineering and tumour medicine fields and discloses an SNP marker related to primary hepatocellular carcinoma auxiliary diagnosis and an application of the SNP marker. The marker is a combination of rs7574865, rs1012068, rs17401966, rs2596542, rs455804, rs9272105, rs9275319 and rs9275572. The marker can be used for preparing a hepatic carcinoma auxiliary diagnosis kit.

The invention relates to a real-time quantitative polymerase chain reaction (PCR) microarray chip kit for forecasting the survival rate after liver cancer operation. The kit is characterized by comprising an IL6 gene amplification primer, an IL6 gene fluorescently tagged probe, an HLA_DRA gene amplification primer, an HLA_DRA gene fluorescently tagged probe, a CSF1 gene amplification primer, a CSF1 gene fluorescently tagged probe, an SPP1 gene amplification primer, an SPP1 gene fluorescently tagged probe, and a tumor necrosis factor (TNF) gene amplification primer and a tumor necrosis factor (TNF) gene fluorescently tagged probe. The invention finds that an IL6 gene, an HLA_DRA gene, a CSF1 gene, an SPP1 gene and a TNF gene can serve as markers to forecast the survival rate after liver cancer operation and provides the corresponding kit. The tissue mRNA levels of patients with primary hepatic carcinoma after operation are detected through a real-time quantitative PCR microarray chip technology. The kit has the advantages of high flux, sensitivity and uniformity, and the like.

The invention relates the method for building mouse primary hepatic carcinoma model. The method comprises the following steps: culturing HepG2 cell in ICR mouse abdominal cavity, pumping ascites, separating cell, making cell suspension, opening mouse abdominal cavity, injecting cell suspension into mouse hepar with microinjector, using 75% alcohol cotton swab to press the hepar, using alpha-cyanoacrylate binding agent to seal pinhole, then using normal saline to wash hepar, closing abdominal cavity. The result displays that the mouse hepar generation rate is 100%, and the natural disappearing rate is 0%. The model can be used to research human primary hepatic carcinoma generation mechanism, and develop antineoplastic.

The invention relates to a composition used for treating liver disease. The composition used for treating the liver disease is mainly prepared from the following raw material medicines: stasis removing grass, cockroach, white paeony root, radix bupleuri, safflower, peach kernel, immature bitter orange, poria cocos, alisma plantago-aquatica, codonopsis pilosula, ricepaper pith, hypericum japonicum, penthorum Chinese pursh, phyla nodiflora, oldenlandia diffusa, sculellaria barbata, fructus amomi, agilawood and liquorice. The composition and adjuvant are made into an oral preparation, the oral operation can be an oral liquid, tablet, capsule, powder or pill; the invention also discloses a preparation method of the composition used for treating the liver disease and the preparation thereof. The composition used for treating the liver disease can be used for treating liver diseases such as hepatitis, cirrhosis, hepatic abscess and primary hepatic carcinoma and has the advantages of obvious effect, small side effect and low repetition rate.

The invention discloses a primary hepatic carcinoma treating pill. The primary hepatic carcinoma treating pill is prepared from, by weight part, 15-25 parts of rumex japonicas, 6-10 parts of rhizoma sparganic with vinegar, 6-10 parts of capillary artemisia, 15-25 parts of sculellaria barbata, 6-10 parts of polyporus umbellatus, 15-25 parts of subprostrate sophora, 15-25 parts of eclipta, 6-10 parts of coxtex moutan, 15-25 parts of caulis spatholobi, 16-22 parts of codonopsis pilosula, 20-25 parts of astragalus membraneceus, 14-16 parts of placenta hominis, 14-16 parts of radix paeoniae alba, 14-16 parts of lycium barbabrum, 16-22 parts of radix bupleuri, 16-22 parts of citrus chirocarpus, 12-18 parts of silybum marianum, 14-16 parts of lysimachia christinae hance, 14-16 parts of corn stigma, 8-12 parts of rhizoma atractylodis macrocephalae, 14-16 parts of fructus aurantii, 16-22 parts of angelica sinensis, 16-22 parts of corydalis tuber, 14-16 parts of red flower, 9-11 parts of salvia miltiorrhiza, 14-16 parts of turtle shell, 14-16 parts of oldenlandia diffusa, 14-16 parts of selfheal, 14-16 parts of dandelion, 9-11 parts of Iphigenia indica, 9-11 parts of green tangerine peel, 6-8 parts of kelp, 4-6 parts of myrrh and 3-5 parts of liquorice. The primary hepatic carcinoma treating pill is prepared from pure Chinese herbs, thereby being low in side and toxic effects and capable of regulating immunity, inhibiting growth of cancer cells, inducing apoptosis and differentiation of the cancer cells, interfering biosynthesis of the cancer cells and inhibiting metastasis and recurrence of liver cancer to achieve the aim of preventing and controlling liver cancer.